首页> 外文期刊>The journal of trauma and acute care surgery >Long-term administration of amnion-derived cellular cytokine suspension promotes functional recovery in a model of penetrating ballistic-like brain injury
【24h】

Long-term administration of amnion-derived cellular cytokine suspension promotes functional recovery in a model of penetrating ballistic-like brain injury

机译:长期服用羊膜来源的细胞因子悬浮液可促进穿透性弹道样脑损伤模型中的功能恢复

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Previous work has shown that human amnion-derived progenitor (AMP) cell therapy is neuroprotective in a penetrating ballistic-like brain injury (PBBI) model. However, the neuroprotective capacity of AMP cells seemed to be mediated by the sustained secretion of AMP cell-derived neurotrophic factors, which are abundant in the amnion-derived cellular cytokine suspension (ACCS). To test this theory, the current study assessed the neuroprotective efficacy of long-term ACCS delivery in the PBBI model. Methods: Experiment 1 assessed the bioactive stability and neuroprotective capacity of ACCS in an in vitro model of neurodegeneration. Experiment 2 evaluated the therapeutic effects of ACCS delivery initiated 15 minutes after PBBI and continued for 2 weeks after injury. Experiment 3 was designed to identify the therapeutic window for long-term ACCS delivery in the PBBI model. Outcome metrics included neurobehavioral assessments and neuropathologic measures of neuroinflammation and axonaleuronal degeneration. Results: Experiment 1 demonstrated that ACCS is thermally stable for 1 week at 37°C and that ACCS treatment protected neurite against staurosporine toxicity. Experiment 2 identified the optimal infusion rate of ACCS (1 μL/h) and demonstrated that long-term infusion of ACCS was capable of promoting significant protection against PBBI-induced neuropathology and motor abnormalities, but was not sufficient for reducing cognitive deficits. Finally, the results of Experiment 3 showed that ACCS is effective in promoting significant neuroprotection even when onset of treatment is delayed out to 24 hours (but not 48 hours) after PBBI. Conclusions: Collectively, our results support the hypothesis that the neuroprotective effects of AMP cells are mediated through a sustained delivery of ACCS, which implicates ACCS as a promising neuroprotection agent for clinical study.
机译:背景:先前的研究表明,人类羊膜来源祖细胞(AMP)细胞疗法在穿透性弹道样脑损伤(PBBI)模型中具有神经保护作用。但是,AMP细胞的神经保护能力似乎是由AMP细胞源性神经营养因子的持续分泌介导的,而这些营养因子在羊膜源性细胞因子悬浮液(ACCS)中丰富。为了验证该理论,当前研究评估了PBBI模型中长期ACCS递送的神经保护功效。方法:实验1评估了ACCS在体外神经变性模型中的生物活性稳定性和神经保护能力。实验2评估了PBBI后15分钟开始的ACCS递送的治疗效果,受伤后持续2周。实验3旨在确定PBBI模型中长期ACCS递送的治疗窗口。结果指标包括神经炎症和轴突/神经元变性的神经行为评估和神经病理学测量。结果:实验1证明ACCS在37°C的温度下可稳定1周,并且ACCS处理可保护神经突免受星形孢菌素的毒性。实验2确定了ACCS的最佳输注速率(1μL/ h),并证明了长期输注ACCS能够促进针对PBBI诱发的神经病理学和运动异常的显着保护,但不足以减少认知缺陷。最后,实验3的结果表明,即使将治疗开始延迟到PBBI后24小时(而不是48小时),ACCS仍可有效地促进明显的神经保护。结论:总的来说,我们的结果支持以下假设:AMP细胞的神经保护作用是通过持续递送ACCS介导的,这暗示ACCS是临床研究中有希望的神经保护剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号